InterMune Phase III Efforts Will Be Funded Through Infergen Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
Proceeds from InterMune’s sale of the hepatitis C agent to Valeant will be used for development of idiopathic pulmonary fibrosis therapies.